

WELCOME

How to survive stem cell transplantation and CAR T-cell therapy

Treatment related mortality and morbidity remain major challenges in stem cell transplantation and in CAR T-cell therapy. Losing a patient's life due to a treatment-related complication is always a tragedy for everybody being involved. The good news is that optimizing prevention and management of complications improves survival and reduces morbidity. The course will specifically focus on practice-based topics that are underrepresented in articles or books. Attendees will get hands on teaching by clinical experts on how to improve competence and skills. After this course, the attendees and their respective patients will be able to survive stem cell transplantation and CAR T-cell therapy.

Zinaida Perić — TCWP, Past Chair

Ivan Moiseev — TCWP, Past Secretary

Olaf Penack — TCWP, Chair-Elect

Lars Klingen Gjørde — TCWP, Secretary

Aron Grubešić — TCWP, Local Organiser

Wednesday, 1 October 2025

16:00 – 18:00 **Scientific Business Meeting**

Thursday, 2 October 2025

08:30 – 08:40

Welcome from the organisers

Zinaida Perić (HR), Ivan Moiseev (RU), Aron Grubešić (HR)

08:40 – 10:00

Session I: Patient journey through allogeneic stem cell transplantation

08:40 – 09:00

Keynote lecture on acute GVHD

Mohamad Mohty (FR)

09:00 – 10:00

Panel discussion

We will interactively go through patient cases. Recognition of complications and their treatment will be covered. Pre-transplant assessment of co-morbidities and risk factors will also be discussed. Finally, we will discuss practical tips for patients recovering from HSCT, supporting patients in return to society, work, family, and their rehabilitation.

Case presentation by Ajna Džanić (HR): Comprehensive nursing care of a Patient with gastrointestinal tract GVHD and associated complications.

Eolia Brissot (FR)

Radovan Vrhovac (HR)

Robert Tićac (HR)

10:00 – 10:30

Industry Symposium by Therakos

ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD

10:00 – 10:20

ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD Q&A

Nicolaus Kröger (DE)

10:20 – 10:30

10:30 – 10:50

Coffee break

10:50 – 12:10

Session II: Prevention of allo-transplant complications

10:50 – 11:10

Keynote lecture

Nicolaus Kröger (DE)

11:10 – 12:10

Panel discussion

Some complications despite major advancements in recent years still pose a significant risk of non-relapse mortality. Currently, we have different transplantation technologies to reduce the risk of GVHD, graft failure and infectious complications. We will discuss existing strategies to improve patients' outcomes and prevent post-transplant complications – as choice of donor, prevention of GVHD and other aspects of transplantation.

Case presentation by Lara Divjak (HR): Mitigating GvHD Risk After Checkpoint Inhibitor Therapy: A Case of PYCy-Based Prophylaxis in CAEBV-Associated HLH.

Ivan Moiseev (RU)

Nadira Duraković (HR)

Dženana Džaferagić (HR)

12:10 – 12:30

Industry Symposium by Takeda

12:10 – 12:30

Cytomegalovirus Under Control – Clinical Challenges and Contemporary Patient Management

Lana Desnica (HR)

12:30 – 13:30

Lunch break

Thursday, 2 October 2025 - continued

13:30 – 14:50	Session III: Patient journey through early complications	
13:30 – 13:50	Keynote on TMA	Rafael Duarte (ES)
13:50 – 14:50	Panel discussion	
	How to recognize and treat infectious and non-infectious complications in the early phase after alloSCT will be presented in an interactive fashion. We will discuss management of VOD/SOS as well as TMA with the participants based on patient cases. We will also focus on organ toxicities, including renal, central nervous and liver manifestations. <i>Case presentation by Ana Bošković (SI): Transplant-Associated Thrombotic Microangiopathy.</i>	Ivan Moiseev (RU) Lana Desnica (HR) Job Rexal Perez Gaddi (HR)
14:50 – 16:10	Session IV: Patient journey through GVHD	
14:50 – 15:10	Keynote lecture (cGVHD section)	Steven Pavletic (US)
15:10 – 16:10	Panel discussion	
	We will discuss management of GVHD with the participants based on patient cases. Recognition of complications and their treatment will be discussed in an interactive fashion. Attendees will improve their skills in diagnosis and grading of GVHD as well as in therapy of acute and chronic steroid-refractory GVHD. In addition, we will give practical tips caring for a patient with GvHD, e.g. on eye, mouth and skin care.	Olaf Penack (DE) Dražen Pulanić (HR) Vedrana Turković (HR) Lucija Jurišić (HR)
16:10 – 16:40	Coffee Break	
16:40 – 18:00	Session V: Patient journey through late effects	
16:40 – 17:00	Keynote on Patient reported outcomes	Hélène Schoemans (BE)
17:00 – 18:00	Panel discussion	
	We will talk about clinical presentation of late effects based on individual patient cases. Attendees will learn how to better detect and manage different late effects including cardiovascular, renal, endocrine, neurological complications, as well as secondary cancer and gender-specific late effects. The basics of assessing symptoms and late effects will be explained, and the use of up-to-date tools to use patient reported outcomes will be discussed.	Lars Klinge Gjærde (DK) Zinaida Perić (HR) Matea Meden (HR)

Friday, 3 October 2025

08:30 – 10:00

Session VI: Patient journey through CAR T-cell therapy

08:30 – 09:00

Keynote lecture

Reuben Benjamin (UK)

09:00 – 10:00

Panel discussion

Using patient cases, we will discuss pre-CART assessment of co-morbidities and risk factors. We will talk about bridging therapy, lymphodepletion, risk for complications and follow up. In an interactive fashion attendees will learn how to manage early and late complications after CAR-T therapy

Charlotte Graham (IT)
Olaf Penack (DE)
Orla Stewart (UK)

10:00 – 10:45

Industry Symposium by Alexion/AstraZeneca Unmasking HSCT-TMA: Complement activation, early diagnosis, and therapeutic innovation

Introduction

Zinaida Perić (HR)

Disease deep dive: pathophysiology and complement activation, C5 inhibitors and therapeutic action

Ivan Moiseev (RU) & Marko Skelin (HR)

Clinical case: recognizing HSCT-TMA early (screening, early diagnosis)

Zinaida Perić (HR) & Anna Sureda (ES)

Panel reflections and key priorities

All Panellists

10:45 – 11:00

Coffee break

11:00 – 12:45

Session VII: Patient journey through CAR T-cell therapy complications

11:00 – 11:30

Keynote lecture

Anna Sureda (ES)

11:30 – 12:45

Panel discussion

We will focus on improving skills in diagnosis and grading of CRS and ICANS as well as cytopenias and infections. We will go through cases with the participants and discuss the prevention, diagnosis, and management of these complications. We will also assess more rare complications as neurological, HLH etc.

Alberto Mussetti (ES)
Paul Ferguson (UK)
Víctor Noriega (ES)

Case presentation by Tajana Grenko Malnar (HR): CAR-T Therapy in Primary CNS Lymphoma: Role of the CAR-HEMATOTOX Score in Predicting and Mitigating Cytopenias and Infections.

12:45 – 13:00

Closing remarks and farewell

Zinaida Perić (HR), Ivan Moiseev (RU), Aron Grubešić (HR)

Industry Symposium Partner



Silver Partner



Bronze Partner

